Here's How ALVO's Commercial Partnerships Are Driving Top-line Growth

Key Takeaways Alvotech's H1 2025 product revenues soared over 200% year over year to nearly $205 million.Teva and Stada alliances powered the rapid uptake of Humira and Stelara biosimilars across the U.S. and EU.New approvals and deals extend Alvotech's pipeline into ophthalmology, neurology and oncology.Biosimilar drugmaker Alvotech (ALVO) has positioned itself differently from other players in the space by using partnerships as its core commercial model. Rather than investing heavily in its own sales infr ...